---
document_datetime: 2025-08-29 14:47:12
document_pages: 31
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/darzalex-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: darzalex-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 17.7586675
conversion_datetime: 2025-12-28 14:11:52.638318
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Darzalex

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                          | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                  |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|--------------------------------------------------------------------------|
| II/0077              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | 19/06/2025                          | 18/07/2025                                  | SmPC and PL                      |                                                                          |
| II/0076              | Extension of indication for Darzalex in combination with bortezomib, lenalidomide and dexamethasone                            | 27/02/2025                          | 04/04/2025                                  | SmPC and PL                      | Please refer to Scientific Discussion 'Darzalex- EMEA/H/C/004077/II/76'. |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           | (D-VRd) for the treatment of adult patients with newly diagnosed multiple myeloma and who are ineligible for stem cell transplant (SCT), based on the results from Study CEPHEUS (54767414MMY3019), a randomised, open-label, active-controlled, multi- centre phase 3 study. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 11.1 of the RMP has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one   |            |     |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IB/0075/G | This was an application for a group of variations. B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.c.1.a - Change in immediate packaging of the AS - Qualitative and/or quantitative composition B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation                                                                                                                                                                                     | 13/11/2024 | n/a |

<div style=\"page-break-after: always\"></div>

| II/0072   | Extension of indication to include Darzalex as a subcutaneous injection in combination with bortezomib, lenalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma, who are eligible for autologous stem cell transplant, based on the primary analysis results from the pivotal study 54767414 / MMY3014 (PERSEUS), a randomised, open-label, active- controlled, multicentre phase 3 study. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 10.1 of the RMP has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or   | 19/09/2024   | 21/10/2024   | SmPC and PL   | Please refer to Scientific Discussion 'Darzalex- EMEA/H/C/004077/II/72.   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|---------------------------------------------------------------------------|
| II/0074   | Update of section 5.1 of the SmPC in order to include the results from the final (overall survival) analysis from study 54767414MMY3008 (MAIA). This is a Phase 3 randomized, open-label, parallel-group, active controlled, multicenter study comparing daratumumab, lenalidomide, and dexamethasone (DRd) vs lenalidomide and dexamethasone (Rd) in subjects with previously untreated multiple myeloma who are ineligible for high dose therapy. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet.                                                                                                                                                                                                                                                                             | 19/09/2024   | 21/10/2024   | SmPC and PL   | Please refer to the Recommendations section above.                        |

<div style=\"page-break-after: always\"></div>

|           | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                |            |            |      |                                                                               |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-------------------------------------------------------------------------------|
| II/0073/G | This was an application for a group of variations. B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal | 18/07/2024 | n/a        |      | Not applicable                                                                |
| IB/0071/G | This was an application for a group of variations. B.I.d.1.z - Stability of AS - Change in the re-test period/storage period or storage conditions - Other variation B.II.f.z - Stability of FP - Other variation B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                      | 20/02/2024 | 21/10/2024 | SmPC |                                                                               |
| II/0070   | Update of section 5.1 of the SmPC in order to update efficacy information based on the final overall survival analysis results from study MMY3007. In addition, the Marketing authorisation holder (MAH) took the opportunity to introduce minor editorial changes.                                                                                                              | 15/02/2024 | 21/10/2024 | SmPC | For more information, please refer to the Summary of Product Characteristics. |

<div style=\"page-break-after: always\"></div>

|           | - Change(s) in the SPC, Labelling or PL due to quality, preclinical, clinical or pharmacovigilance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |            |      | C.I.4 new data         |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|------------------------|
| IB/0069/G | This was an application for a group of variations. B.II.f.z - Stability of FP - Other variation B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 14/11/2023 | 25/01/2024 | SmPC | stability protocol     |
| IB/0068/G | This was an application for a group of variations. B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.III.2.a.2 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material B.III.2.z - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Other variation B.III.2.z - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Other variation B.III.2.z - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Other variation B.III.2.z - Change to comply with Ph. Eur. or with a | 17/10/2023 | n/a        |      | national pharmacopoeia |

<div style=\"page-break-after: always\"></div>

|                     | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                    |            |     |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| IA/0067/G           | This was an application for a group of variations. B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits | 30/06/2023 | n/a |                                   |
| PSUSA/10498 /202211 | Periodic Safety Update EU Single assessment - daratumumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 08/06/2023 | n/a | PRAC Recommendation - maintenance |
| II/0066             | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 26/04/2023 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|         | of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |            |             |                                                                                                                                                                                                                                                           |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0064 | Update of section 5.1 of the SmPC following submission of the final report from study MMY3013 (54767414MMY3013). This is a Phase III, randomized, open-label study comparing daratumumab, pomalidomide and low-dose dexamethasone (DaraPomDex) with pomalidomide and low-dose dexamethasone (PomDex) in subjects with relapsed or refractory multiple myeloma who have received at least 1 prior treatment regimen with both lenalidomide and a proteasome inhibitor and have demonstrated disease progression. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority | 09/02/2023 | 25/01/2024 | SmPC        |                                                                                                                                                                                                                                                           |
| II/0063 | Update of sections 4.4 and 4.8 of the SmPC in order to update the warnings and precautions for ocular events following PSUSA/00010498/202111, based on the cumulative review of the relevant cases retrieved from the MAH's global safety database, clinical database, epidemiological evaluation and literature review. In addition, the MAH took the opportunity for a minor correction in section 6.3 SmPC. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                              | 09/02/2023 | 25/01/2024 | SmPC and PL | Daratumumab infusion should be interrupted in patients experiencing ocular adverse and immediate ophthalmologic evaluation should be sought before restarting the infusion. For more information, please refer to the Summary of Product Characteristics. |

<div style=\"page-break-after: always\"></div>

| II/0062             | Update of section 4.8 of the SmPC in order to add COVID-19 to the list of adverse drug reactions (ADRs) with frequency common, based on a pooled dataset from the following interventional studies 4767414MMY2004, 54767414MMY3003, 54767414MMY3006, 54767414MMY3008, and 54767414MMY3013. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   | 24/11/2022   | 10/01/2023   | SmPC and PL   | Not applicable                                                                                                                                                                                                                            |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0061/G           | This was an application for a group of variations. A.6 - Administrative change - Change in ATC Code/ATC Vet Code B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol                                                                                                                                                                                                                                                                     | 30/06/2022   | 10/01/2023   | SmPC          |                                                                                                                                                                                                                                           |
| PSUSA/10498 /202111 | Periodic Safety Update EU Single assessment - daratumumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 10/06/2022   | n/a          |               | PRAC Recommendation - maintenance                                                                                                                                                                                                         |
| II/0060/G           | This was an application for a group of variations. C.I.4: Update of section 5.1 of SmPC to include the final overall survival (OS) results based on the final OS analysis for pivotal study 54767414MMY3003                                                                                                                                                                                                                                                                                                                                                              | 02/06/2022   | 10/01/2023   | SmPC          | SmPC new text in section 5.1 Study MMY3003: After a median follow-up of 80 months, DRd has shown an OS advantage over the Rd arm (HR=0.73; 95% CI: 0.58, 0.91; p=0.0044), The median OS was 67.6 months in the DRd arm and 51.8 months in |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| (MMY3003). MMY3003 (Pollux) is an open-label, randomized, active-controlled Phase III study that compared treatment with DARZALEX 16mg/kg in combination with lenalidomide and low-dose dexamethasone (DRd) to treatment with lenalidomide and low-dose dexamethasone (Rd) in patients with relapsed or refractory multiple myeloma who had received at least one prior therapy. C.I.4: Update of section 5.1 of SmPC to include the final overall survival (OS) results based on the final OS analysis for pivotal Studies 54767414MMY3004 (MMY3004). MMY3004 (Castor) is a Phase III, multicenter, randomized, open-label, active- controlled study comparing daratumumab in combination with bortezomib and dexamethasone (DVd) with bortezomib and dexamethasone (Vd) in subjects with relapsed or refractory multiple myeloma. In addition, the MAH took the opportunity to implement some editorial changes. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance   | the Rd arm. Study MMY3004: After a median follow-up of 73 months, DVd has shown an OS advantage over the Vd arm (HR=0.74; 95% CI: 0.59, 0.92; p=0.0075). The median OS was 49.6 months in the DVd arm and 38.5 months in the Vd arm. For more information, please refer to the Summary of Product Characteristics.   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| II/0059/G   | This was an application for a group of variations. B.I.a.1.e - Change in the manufacturer of AS or of a                                                 | 12/05/2022   | 10/01/2023   | Annex II    | The Annex II has been updated as follows: Addition of Janssen Sciences Ireland UC, Barnahely, Ringaskiddy, Cork, Ireland as manufacturer of a biological   |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0057     | B.II.f.1.b.2 - Stability of FP - Extension of the shelf life of the finished product - After first opening (supported by real time data)                | 26/02/2022   | 10/01/2023   | SmPC and PL |                                                                                                                                                            |
| II/0053     | C.I.4 Update of section 5.1 of the SmPC in order to update PFS and OS) data based on interim results from study MMY3008; This is a Phase 3, randomized, | 24/02/2022   | 10/01/2023   | SmPC        | The table in Module 8b of the EPAR will be updated as follows: Scope Please refer to the Recommendations section above                                     |

<div style=\"page-break-after: always\"></div>

|           | open-label, active controlled, parallel-group, multicenter study in adults with newly diagnosed MM not eligible for ASCT comparing DRd vs Rd. The Marketing authorisation holder (MAH) took the opportunity to make minor formatting and linguistic changes in the PI. is recommended for approval. Amendments to the marketing authorisation In view of the data submitted with the variation, amendments to Annex(es) I are recommended. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |            |                   | SmPC new text: In section 5.1 for study MMY3008 PFS data are updated and OS data are added Results of an updated PFS analysis after a median follow-up of 64 months continued to show an improvement in PFS for patients in the DRd arm compared with the Rd arm. Median PFS was 61.9 months in the DRd arm and 34.4 months in the Rd arm (HR=0.55; 95% CI: 0.45, 0.67). With a median follow-up of 56 months, DRd has shown an OS advantage over the Rd arm (HR=0.68; 95% CI: 0.53, 0.86; p=0.0013). Results of an updated OS analysis after a median of 64 months continued to show an improvement in OS for patients in the DRd arm compared to the Rd arm. Median OS was not reached in the DRd arm and was 65.5 months in the Rd arm (HR= 0.66; 95% CI: 0.53, 0.83). For more information, please refer to the Summary of Product Characteristics.   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0056/G | This was an application for a group of variations. B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol A.4 - Administrative change - Change in the name             | 20/01/2022 | 10/01/2023 | SmPC and Annex II |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

|           | or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                                                                                                                                                                                                                                                                        |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0054    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 11/11/2021 | 06/01/2022 | SmPC, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Darzalex in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. Darzalex (daratumumab) is removed from the additional monitoring list as a new active substance and new biological following five years of authorisation. PI is brought in line with the latest QRD template.                                                                                                                               |
| IB/0055   | B.I.z - Quality change - Active substance - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 09/11/2021 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| II/0051/G | This was an application for a group of variations. C.I.4 Update of section 5.1 of the SmPC in order to update PFS data based on interim results from study MMY3006 (CCO 27/8/2020); this is a Phase 3, randomized, open-label, parallel-group, active- control, multi-center study of daratumumab combined with VTd for NDMM patients eligible for ASCT. This fulfils a post-approval commitment of procedure EMEA/H/C/004077//II/0030 to provide updated Part 1 PFS data, with censoring the patients randomized to daratumumab in Part 2 of this study. C.I.4 | 07/10/2021 | 06/01/2022 | SmPC                   | SmPC new text Section 5.1 Update of PFS for study MMY3006 Results of an updated PFS analysis with a median follow-up of 44.5 months, censoring patients who were randomised to daratumumab maintenance in the second randomisation, showed HR=0.43; 95% CI: 0.33, 0.55; p<0.0001. Median PFS was not reached in the D VTd arm and was 37.8 months in the VTd arm. Update of OS for study MMY3012 After a median follow-up of 29.3 months, the median OS was 28.2 months (95% CI: 22.8, NE) in the DARZALEX subcutaneous formulation arm and was 25.6 months (95% CI: 22.1, NE) in the intravenous daratumumab arm. |

<div style=\"page-break-after: always\"></div>

|         | Update of section 5.1 of the SmPC of DARZALEX SC formulation to provide the mature OS data based on final results from study MMY3012 (CCO 04/11/2020); this is a Phase 3, multi-center, randomized, open-label, active-controlled study to demonstrate that the efficacy and PK for daratumumab SC are not inferior to those for daratumumab IV in subjects with RRMM submitted for the approval of the SC formulation in procedure EMEA/H/C/004077//II/0032 C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance   |            |            |                        | For more information, please refer to the Summary of Product Characteristics.                                                                                                                                                                                                                                                                                |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0050 | C.I.4 Update of section 4.8 of the SmPC in order to add hypogammaglobulinemia to the list of adverse drug reactions (ADRs) with frequency common, based on new information and previously reviewed pooled safety data from Part 2 of Phase 3 Clinical Study 54767414MMY3006 comparing daratumumab versus observation as maintenance in patients with newly diagnosed Multiple Myeloma who are post-ASCT transplant. The Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance                                                                                                                  | 07/10/2021 | 06/01/2022 | SmPC, Labelling and PL | SmPC new text Section 4.8 Addition of a new ADR: System Organ Class Adverse reaction Frequency Incidence (%) Any Grade Grade 3 4 Intravenous formulation Immune system disorders Hypogammaglobulinemia Common 3 <1* Subcutaneous formulation Immune system disorders Hypogammaglobulinemia Common 2 <1# For more information, please refer to the Summary of |

<div style=\"page-break-after: always\"></div>

|           | data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |            |                                  | Product Characteristics.   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|----------------------------|
| IB/0052/G | This was an application for a group of variations. B.II.c.4.z - Change in synthesis or recovery of a non- pharmacopoeial or novel excipient - Other variation B.II.c.1.a - Change in the specification parameters and/or limits of an excipient - Tightening of specification limits B.II.c.z - Change in control of excipients in the Finished Product - Other variation B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product B.II.c.2.a - Change in test procedure for an excipient                        | 23/08/2021 | n/a        |                                  |                            |
| II/0049/G | This was an application for a group of variations. B.II.b.3.c - Change in the manufacturing process of the finished or intermediate product - The product is a biological/immunological medicinal product and the change requires an assessment of comparability B.II.a.3.b.3 - Changes in the composition (excipients) of the finished product - Other excipients - Change that relates to a biological/immunological product A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of | 22/07/2021 | 06/01/2022 | SmPC, Annex II, Labelling and PL |                            |

<div style=\"page-break-after: always\"></div>

|           | manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |            |             |                                                                    |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------|
| II/0048/G | This was an application for a group of variations. B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time                                                                                                                                                                                                                                       | 24/06/2021 | n/a        |             |                                                                    |
| II/0044   | Extension of indication for Darzalex subcutaneous formulation to include combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide- refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy; as a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. In addition, section 4.8 of the SmPC for the intravenous formulation is also updated based on the pooled | 20/05/2021 | 21/06/2021 | SmPC and PL | Please refer to Scientific Discussion Darzalex-H-C-004077- II-0044 |

<div style=\"page-break-after: always\"></div>

|         | safety analysis. The Package Leaflet is updated in accordance. Version 8.2 of the RMP has also been submitted. The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP). Amendments to the marketing authorisation In view of the data submitted with the variation, amendments to Annex(es) I and IIIB and to the Risk Management Plan are recommended. Similarity with authorised orphan medicinal products The CHMP by consensus is of the opinion that Darzalex is not similar to Imnovid, Farydak, Kyprolis, Ninlaro and Blenrep within the meaning of Article 3 of Commission Regulation (EC) No. 847/200. See appendix 1 C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or   |            |            |             |                                                                     |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------|
| II/0043 | Outcome Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends by consensus the variation to the terms of the Marketing Authorisation, concerning the following change: Variation accepted Type Annexes affected C.I.6.a C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic                                                                                                                                                                                                                                                                                                                                                                                                                                  | 20/05/2021 | 21/06/2021 | SmPC and PL | Please refer to Scientific Discussion 'Darzalex H-C-004077- II-0043 |

<div style=\"page-break-after: always\"></div>

|         | I and IIIB Extension of indication to include treatment of adult patients with newly diagnosed systemic light chain (AL) amyloidosis in combination with cyclophosphamide, bortezomib and dexamethasone; The variation leads to amendments to the Summary of Product Characteristics, Annex II, Package Leaflet and to the Risk Management Plan (RMP). Amendments to the marketing authorisation In view of the data submitted with the variation, amendments to Annex(es) I, II and IIIB and to the Risk Management Plan are recommended. Similarity with authorised orphan medicinal products Not applicable. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or   |            |            |                        |                                                                                                                                                                                                                                                                                                                                                           |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0047 | C.I.4 Update of section 4.4 of the SmPC in order to to include a fatal outcome for IRRs following a systematic cross-programmatic review of fatal cases of Infusion Related Reaction (IRR) with use of daratumumab. In addition, the MAH has taken the opportunity to correct in section 4.8 the reported incidence rate of Grade 3 or 4 treatment-emergent infections from Study MMY3003 for DRd from 27% to 28%. In addition, the marketing authorisation holder has taken the opportunity to update the list of local representatives in the PL and implement minor                                                                                                                                           | 20/05/2021 | 21/06/2021 | SmPC, Labelling and PL | Summary Please refer to Scientific Discussion 'Darzalex-H-C-004077- II-0047' In Section 4.4 Special warnings and precautions for use under the paragraph Infusion related reactions The following sentence was added: These reactions can be life-threatening and fatal outcomes have been reported. For more information, please refer to the Summary of |

<div style=\"page-break-after: always\"></div>

|                     | is recommended for approval. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                    |            |            |                        | Product Characteristics.          |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| PSUSA/10498 /202011 | Periodic Safety Update EU Single assessment - daratumumab                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 06/05/2021 | n/a        |                        | PRAC Recommendation - maintenance |
| II/0040             | B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol                                                                                                                                                                                                                                                        | 14/01/2021 | n/a        |                        |                                   |
| IB/0045             | B.II.e.2.z - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                            | 17/12/2020 | n/a        |                        |                                   |
| II/0041             | Update of section 4.8 of the SmPC in order to include CMV infections as a new adverse drug reaction (ADR) with frequency common following a comprehensive, cross-program evaluation of all potential cases of treatment-emergent cytomegalovirus (CMV) infections with use of daratumumab. The Package Leaflet is updated accordingly. Several minor linguistic improvements are also proposed. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 03/12/2020 | 21/06/2021 | SmPC, Labelling and PL |                                   |

<div style=\"page-break-after: always\"></div>

| IB/0042   | B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 05/11/2020   | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                    |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0038   | Update section 4.8 of the SmPC in order to add sepsis with frequency common as an ADR and incidence data on fatal infections and adverse reactions in the elderly patients based on cross- programmatic review of data. The MAH also proposed minor corrections in section 4.8 of the SPC. The Package Leaflet and labelling is updated accordingly. Correction of Annex II to add the active substance manufacturer 'Samsung Biologics, Korea', which was overlooked during procedure II-018 (approved on 11 July 2019) C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 09/07/2020   | 21/06/2021 | SmPC, Annex II, Labelling and PL | SmPC new text: Section 4.8 Sepsis is added to the list of adverse drug reactions (ADRs) in safety summary profile and in table 5 with frequency common Information was added on the incidence of a) fatal infections in patients receiving DARZALEX combination therapy b) adverse reactions in the elderly patients For more information, please refer to the Summary of Product Characteristics. |
| II/0039   | Update of section 5.1 of the SmPC in order to update information regarding immunogenicity following completion of post-authorization commitments regarding re-analysis of all ADA samples taken from previously submitted clinical using the Enhanced DT Method (previously developed as a result of PAM- MEA-005). The Important Potential Risk of immunogenicity is removed from the RMP and                                                                                                                                                                                                                                             | 11/06/2020   | 21/06/2021 | SmPC                             | SmPC new text Section 5.1. Immunogenicity In patients treated with subcutaneous daratumumab in clinical trials, less than 1% of patients developed treatment-emergent anti-daratumumab antibodies. For more information, please refer to the Summary of Product Characteristics.                                                                                                                   |

<div style=\"page-break-after: always\"></div>

|                     | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required                                                                                                                                         |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10498 /201911 | Periodic Safety Update EU Single assessment - daratumumab                                                                                                                                                                                                                                                                                                                                                                              | 11/06/2020 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| X/0032              | Annex I_2.(c) Change or addition of a new strength/potency Annex I_2.(d) Change or addition of a new pharmaceutical form Annex I_2.(e) Change or addition of a new route of administration                                                                                                                                                                                                                                             | 30/04/2020 | 03/06/2020 | SmPC, Annex II, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| IB/0036             | B.I.b.2.c - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure for a reagent, which does not have a significant effect on the overall quality of the AS                                                                                                                                                                                                                     | 30/03/2020 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| II/0035             | Update of section 5.1 of the SmPC in order to update efficacy information based on interim results from phase III follow up studies of 3 approved combination treatments of daratumab (D) in relapsed or refractory MM patients MMY3003 (DRd vs Rd) and MMY3004 (DVd vs Vd) and in newly diagnosed MM patients MMY3007 (DVd vs Vd). In addition, the Marketing authorisation holder (MAH) took the opportunity to introduce some minor | 26/03/2020 | 03/06/2020 | SmPC and PL                      | In Study MMY3007: Results of an updated PFS analysis after a median follow up of 40 months continued to show an improvement in PFS for patients in the D VMP arm compared with the VMP arm. Median PFS was 36.4 months in the D VMP arm and 19.3 months in the VMP arm (HR=0.42; 95% CI: 0.34, 0.51; p<0.0001), representing a 58% reduction in the risk of disease progression or death in patients treated with D VMP. D VMP has shown an overall survival (OS) advantage over the VMP arm (HR=0.60; 95% |

<div style=\"page-break-after: always\"></div>

|         | editorial changes in the PI and to update the list of local representatives for Italy in the Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                  |            |            |                    | CI: 0.46, 0.80; p=0.0003), representing a 40% reduction in the risk of death in patients treated in the D VMP arm. Median OS was not reached for either arm In Study MMY3003: Results of an updated PFS analysis after a median follow up of 55 months continued to show an improvement in PFS for patients in the DRd arm compared with the Rd arm. Median PFS was 45.0 months in the DRd arm and 17.5 months in the Rd arm (HR=0.44; 95% CI: 0.35, 0.54; p<0.0001), representing a 56% reduction in the risk of disease progression or death in patients treated with DRd In Study MMY3004: Results of an updated PFS analysis after a median follow up of 50 months continued to show an improvement in PFS for patients in the DVd arm compared with the Vd arm. Median PFS was 16.7 months in the DVd arm and 7.1 months in the Vd arm (HR [95% CI]: 0.31 [0.24, 0.39]; p-value<0.0001), representing a 69% reduction in the risk of disease progression or death in patients treated with DVd versus Vd For more information, please refer to the Summary of Product Characteristics.   |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0030 | Extension of indication in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant (ASCT) for Darzalex; as a consequence, sections 4.1, 4.2, 4.5, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. The RMP (version 6.4) has | 12/12/2019 | 20/01/2020 | SmPC and Labelling | Please refer to the Scientific Discussion Darzalex-H-C- 4077-II-0030                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

|           | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |            |                       |                                                                      |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|----------------------------------------------------------------------|
| IA/0034   | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 29/11/2019 | n/a        |                       |                                                                      |
| II/0033   | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 28/11/2019 | n/a        |                       |                                                                      |
| II/0029   | Extension of indication in combination with lenalidomide and dexamethasone (Rd) for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT) for Darzalex; as a consequence, sections 4.1, 4.2, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. The RMP has been updated accordingly (finally agreed version 6.2). Furthermore, the Annex II is brought in line with the latest QRD template version 10.1. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | 17/10/2019 | 19/11/2019 | SmPC, Annex II and PL | Please refer to the Scientific Discussion Darzalex-H-C- 4077-II-0029 |
| II/0018/G | This was an application for a group of variations. B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 11/07/2019 | n/a        |                       |                                                                      |

<div style=\"page-break-after: always\"></div>

|                     | change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product B.I.a.2.b - Changes in the manufacturing process of the AS - Substantial change to the manufacturing process of the AS which may have a significant impact on the quality, safety or efficacy of the medicinal product                                                                                                    |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0027             | Update of sections 4.4 and 4.8 of the SmPC to introduce a new warning and to add the recently identified risk of Hepatitis B reactivation as an uncommon adverse drug reaction, respectively. The PL and the RMP (v. 5.0 rev2) are amended accordingly. A DHPC to inform prescribers on the newly identified risk has been agreed. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 29/05/2019 | 28/06/2019 | SmPC and PL | Hepatitis B virus reactivation, in some cases fatal, has been reported in patients treated with DARZALEX. HBV screening should be performed in all patients before initiation of treatment with DARZALEX. For patients with evidence of positive HBV serology, monitor for clinical and laboratory signs of HBV reactivation during, and for at least six months following the end of DARZALEX treatment. Manage patients according to current clinical guidelines. Consider consulting a hepatitis disease expert as clinically indicated. In patients who develop reactivation of HBV while on DARZALEX, suspend treatment with DARZALEX and institute appropriate treatment. Resumption of DARZALEX treatment in patients whose HBV reactivation is adequately controlled should be discussed with physicians with expertise in managing HBV. |
| PSUSA/10498 /201811 | Periodic Safety Update EU Single assessment - daratumumab                                                                                                                                                                                                                                                                                                                                                                                            | 14/06/2019 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| IB/0031             | B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation                                                                                                                                                                                                                                                                                                                                                                         | 29/04/2019 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

| IB/0028   | B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation                                                                                                                                                                                                                                                                                                                                       | 08/04/2019   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0020   | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                      | 17/01/2019   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| IB/0025/G | This was an application for a group of variations. B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data B.I.d.1.z - Stability of AS - Change in the re-test period/storage period or storage conditions - Other variation                                                                        | 18/12/2018   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| II/0019   | Update of sections 4.2, 4.8 and 5.2 of the SmPC in order to include the possibility for a split first dose for the treatment of patients with multiple myeloma, based on the Phase 1b open-label, non-randomised, multicentre Study 54767414MMY1001. The package leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 15/11/2018   | 18/12/2018 | SmPC and PL | In Study MMY1001, patients receiving daratumumab combination treatment (n=97) were administered the first 16 mg/kg daratumumab dose at Week 1 split over two days i.e. 8 mg/kg on Day 1 and Day 2 respectively. The incidence of any grade infusion-related reactions was 42%, with 36% of patients experiencing infusion-related reactions on Day 1 of Week 1, 4% on Day 2 of Week 1, and 8% with subsequent infusions. The median time to onset of a reaction was 1.8 hours (range: 0.1 to 5.4 hours). The incidence of infusion interruptions due to reactions was 30%. Median durations of infusions were 4.2 h for Week 1- Day 1, 4.2 h for Week 1-Day 2, and 3.4 hours for the subsequent infusions. Simulation of daratumumab pharmacokinetics was conducted for all recommended dosing schedules in 1,309 |

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                                                                                                                                    |            |            |                        | patients with multiple myeloma. The simulation results confirmed that the split and single dosing for the first dose provide similar PK, with the exception of the PK profile in the first day of the treatment. In conclusion and in order to facilitate administration, the first prescribed 16 mg/kg dose of daratumumab at Week 1 may be split over two consecutive days i.e. 8 mg/kg on Day 1 and Day 2, respectively.   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0023             | B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes | 13/12/2018 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                               |
| IB/0022             | B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes                                                                                                | 30/11/2018 | 28/06/2019 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                               |
| PSUSA/10498 /201805 | Periodic Safety Update EU Single assessment - daratumumab                                                                                                                                                                                                                                          | 29/11/2018 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                             |
| N/0024              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                   | 12/10/2018 | 18/12/2018 | PL                     |                                                                                                                                                                                                                                                                                                                                                                                                                               |
| II/0011             | Extension of Indication to include the combination with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous                                                                                           | 26/07/2018 | 31/08/2018 | SmPC and PL            | Please refer to the Scientific Discussion - Darzalex II-11.                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

|                     | stem cell transplant for Darzalex; as a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. The RMP is updated to version 3.2 (in version 2 of the RMP template). In addition, the Marketing authorisation holder took the opportunity to update Annex II with regards to PSUR requirements and to update the contact details of the Lithuanian and Slovenian local representatives in the Package Leaflet. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one   |            |            |             |                                                                                                                                                                                 |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10498 /201711 | Periodic Safety Update EU Single assessment - daratumumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 14/06/2018 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                               |
| IAIN/0016/G         | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                          | 18/05/2018 | n/a        |             |                                                                                                                                                                                 |
| II/0013             | Update of section 4.8 of the Darzalex SmPC in order to add anaphylactic reactions with a frequency 'rare' as new adverse reactions and update of section 4.4                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 03/05/2018 | 31/08/2018 | SmPC and PL | Darzalex can cause serious infusion related reactions (IRRs), including anaphylactic reactions. All patients should be monitored throughout the infusion for IRRs. For patients |

<div style=\"page-break-after: always\"></div>

|         | to complement the existing warning on infusion related reactions based on the cumulative review of clinical trial and post-marketing data. The Package Leaflet (PL) is updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to add in section 4.4 the traceability statement of biological medicines to bring the product information in line with the guideline on good pharmacovigilance practices and to add specific text relating to the excipient sodium to align the product information with the updated published EMA EU excipient guideline. The MAH also took the opportunity to update the PL with revised contact details of local representative for Czech Republic and Portugal. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance   |            |            |      | that experience any Grade IRRs, continue monitoring post- infusion until symptoms resolve. In clinical trials IRRs were reported in approximately half of all patients treated with Darzalex. The majority of IRRs occurred at the first infusion and were Grade 1-2. Patients should be pre medicated with antihistamines, antipyretics and corticosteroids to reduce the risk of IRRs prior to treatment with Darzalex. Darzalex infusion should be interrupted for IRRs of any severity and medical management/supportive treatment for IRRs should be instituted as needed. For patients with Grade 1, 2, or 3 IRRs, the infusion rate should be reduced when re starting the infusion. If an anaphylactic reaction or life threatening (Grade 4) infusion reaction occurs, appropriate emergency resuscitation should be initiated immediately. Darzalex therapy should be discontinued immediately and permanently.   |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0014 | Update of section 4.5 of the SmPC in order to add information relating to the daratumumab interference with Serum Protein Electrophoresis (SPE) and Immunofixation (IFE) assays and the daratumumab-specific immunofixation reflex assay (DIRA). C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 15/03/2018 | 25/06/2018 | SmPC | Daratumumab may be detected on serum protein electrophoresis (SPE) and immunofixation (IFE) assays used for monitoring disease monoclonal immunoglobulins (M protein). This can lead to false positive SPE and IFE assay results for patients with IgG kappa myeloma protein impacting initial assessment of complete responses by International Myeloma Working Group (IMWG) criteria. In patients with persistent very good partial response, where daratumumab interference is suspected, consider using a validated daratumumab-specific IFE assay to distinguish daratumumab from any remaining endogenous M protein in the patient's serum, to facilitate determination of a                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |            |          | complete response.                |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|-----------------------------------|
| IB/0012             | B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 21/12/2017 | n/a        |          |                                   |
| PSUSA/10498 /201705 | Periodic Safety Update EU Single assessment - daratumumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 30/11/2017 | n/a        |          | PRAC Recommendation - maintenance |
| IB/0010             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 19/09/2017 | n/a        |          |                                   |
| IB/0008/G           | This was an application for a group of variations. B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol B.II.f.1.e - Stability of FP - Change to an approved | 02/08/2017 | 25/06/2018 | SmPC     |                                   |
| IA/0007/G           | This was an application for a group of variations. A.4 - Administrative change - Change in the name                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 16/06/2017 | 25/06/2018 | Annex II |                                   |

<div style=\"page-break-after: always\"></div>

|                     | and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |            |                       |                                                                             |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|-----------------------------------------------------------------------------|
| PSUSA/10498 /201611 | Periodic Safety Update EU Single assessment - daratumumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 09/06/2017 | n/a        |                       | PRAC Recommendation - maintenance                                           |
| II/0002             | Extension of Indication for Darzalex in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 5.1 and 5.2 of the SmPC are updated in order to update the information on the target patient population, posology, warnings, interactions, efficacy and pharmacokinetics. A new warning is introduced in section 4.4 regarding neutropenia/thrombocytopenia induced by background therapy. Furthermore, the CHMP is of the opinion that all specific obligations have been fulfilled following submission of the final results of studies MMY3003 and MMY3004 and in light of the data generated and the evidence of compliance with the specific obligations, the CHMP recommends the granting of a marketing authorisation in accordance with Article | 23/02/2017 | 28/04/2017 | SmPC, Annex II and PL | Please refer to the Scientific Discussion Darzalex EMEA/H/C/004077/II/0002. |

<div style=\"page-break-after: always\"></div>

|           | updated to remove the fulfilled specific obligations. The Package Leaflet and Risk Management Plan (RMP version 2.1) are updated in accordance. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one   |            |            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0003    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                         | 23/02/2017 | 24/04/2017 | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations assessed through variation II-02 and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated. Furthermore, in the framework of the variation II-02, the CHMP concludes that the remaining specific obligations for the Conditional Marketing Authorisation are fulfilled and recommends granting a Marketing Authorisation no longer subject to specific obligations. |
| II/0005/G | This was an application for a group of variations. B.II.b.3.c - Change in the manufacturing process of the finished or intermediate product - The product is a biological/immunological medicinal product and the change requires an assessment of comparability B.II.b.4.c - Change in the batch size (including batch size ranges) of the finished product - The change                                                       | 06/04/2017 | n/a        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

|           | biological/immunological medicinal product or a new bioequivalence study                                                                                                                                                                                                                                                   |            |     |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| II/0004   | B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol                                                                 | 23/02/2017 | n/a |
| IA/0001/G | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure | 01/09/2016 | n/a |